In this episode of omg OMx, Mike Greig from Bruker discusses the potential of mass spectrometry in pharma. He talks about his career in biotechnology, his mentor, and his passion for chemistry. He also discusses the evolution of drug development and the barriers to the marketability of mass spectrometry in the pharma industry. He mentions the advancements in drug discovery and the improvements in mass spec technology over the years. Greig also emphasizes the importance of ease of use and software in mass spectrometry. The episode provides insights into the applications and innovations in mass spectrometry for analytical challenges in the field of life sciences.
Source link
When mass spectrometry redefines the pharma industry
